Section 1 - Identification of the Substance/Mixture and Supplier

Zoetis Australia Pty Ltd

Product Identifier: EAZI-BREED CIDR® Sheep and Goat Device

APVMA Code: 49895

Other names: None

Chemical family: Delivers progesterone which is a female sex hormone

Recommended Use: Intravaginal hormonal device for oestrus synchronisation (controlled breeding) in sheep and goats.

Restrictions on use: For veterinary use only

Emergency Phone: 1800 814 883 (all hours)

Section 2 - Hazards Identification

Appearance: Solid

Classification of the Substance or Mixture

GHS - Classification
Reproductive Toxicity: Category 1B
Carcinogenicity: Category 1B

Label Elements

Signal Word: Danger
Hazard Statements:
H350 - May cause cancer
H360 - May damage fertility or the unborn child

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.

Known Clinical Effects: Based on human experience, possible adverse effects following exposure to this compound may include menstrual irregularities weight changes fluid retention drowsiness, sleepiness, dizziness, sedation, and gastrointestinal disturbance.

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### Section 3 - Composition/Information on Ingredients

<table>
<thead>
<tr>
<th>Hazardous Ingredients</th>
<th>CAS No</th>
<th>Conc,%</th>
<th>GHS Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progesterone</td>
<td>57-83-0</td>
<td>0.30 gm/insert</td>
<td>Carc. 1B (H350) Repr. 1B (H360FD)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS No</th>
<th>Conc,%</th>
<th>GHS Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silicone rubber</td>
<td>63394-02-5</td>
<td>*</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Nylon 66</td>
<td>32131-17-2</td>
<td>*</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

**Additional Information:** * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

This is a commercial product whose exact ratio of components may vary slightly. Minor quantities of other non-hazardous ingredients are also possible.

### Section 4 - First Aid Measures

**Description of First Aid Measures**

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, see Section 2 – Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:**
None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None
Section 5 - Fire Fighting Measures

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Not available

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Section 6 - Accidental Release Measures

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Section 7 - Handling and Storage

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None known

Specific end use(s): No data available

Section 8 - Exposure Controls and Personal Protection

Control Parameters
Progestrone
Zoetis OEL TWA 8-hr                                                                 30 μg/m³ Skin

**Exposure Controls**

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

---

**Section 9 - Physical and Chemical Properties:**

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Solid</th>
<th>Color:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Solvent Solubility:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
</tr>
</tbody>
</table>

**Partition Coefficient: (Method, pH, Endpoint, Value)**

<table>
<thead>
<tr>
<th>Method</th>
<th>pH</th>
<th>Endpoint</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Progesterone**

<table>
<thead>
<tr>
<th>Odor Threshold:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predicted</td>
<td>7.4</td>
</tr>
</tbody>
</table>

**Decomposition Temperature (°C):**

| No data available |

<table>
<thead>
<tr>
<th>Evaporation Rate (Gram/s):</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml):</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative Density:</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity:</td>
<td>No data available</td>
</tr>
</tbody>
</table>

**Flammability:**

| Autoignition Temperature (Solid) (°C): | No data available |
| Flammability (Solids):                | No data available |
| Flash Point (Liquid) (°C):            | No data available |
| Upper Explosive Limits (Liquid) (% by Vol.): | No data available |
| Lower Explosive Limits (Liquid) (% by Vol.): | No data available |

---

**Section 10 - Stability and Reactivity**

<table>
<thead>
<tr>
<th>Reactivity:</th>
<th>No data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Stability:</td>
<td>Stable under normal conditions of use.</td>
</tr>
<tr>
<td>Possibility of Hazardous Reactions</td>
<td>None</td>
</tr>
</tbody>
</table>

**SAFETY DATA SHEET**

Issued by: Zoetis Australia Pty Ltd Phone: 1800 814 883

Poisons Information Centre: 13 11 26 from anywhere in Australia
Section 11 - Toxicological Information

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Acute Toxicity: (Species, Route, End Point, Dose)

Progesterone

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>LD₅₀</td>
<td>&gt;5000 mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Sub-tenon injection (eye)</td>
<td>LD₅₀</td>
<td>327 mg/kg</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Progesterone

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose Description</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Year(s)</td>
<td>Rabbit</td>
<td>Intramuscular</td>
<td>13 mg/kg</td>
<td>LOEL Female reproductive system</td>
</tr>
<tr>
<td>74 Week(s)</td>
<td>Dog</td>
<td>Subcutaneous</td>
<td>0.08-22.5 mg/day (increased dose)</td>
<td>LOEL Female reproductive system</td>
</tr>
</tbody>
</table>

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Progesterone

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose Description</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproductive &amp; Fertility</td>
<td>Rabbit</td>
<td>No route specified</td>
<td>Dose not specified</td>
<td>Embryotoxicity</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>No route specified</td>
<td>Dose not specified</td>
<td>Not Teratogenic</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Monkey</td>
<td>No route specified</td>
<td>Dose not specified</td>
<td>Not Teratogenic</td>
</tr>
</tbody>
</table>

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

- Bacterial Mutagenicity (Ames): Negative
- In Vivo Dominant Lethal Assay Mouse: Negative
- In Vivo Chromosome Aberration Rat: Negative
- In Vitro Chromosome Aberration Human: Negative
- In Vitro Cell Transformation Assay Rat: Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Progesterone

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose Description</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Year(s)</td>
<td>Rabbit</td>
<td>Intramuscular</td>
<td>13 mg/kg</td>
<td>NOEL Not carcinogenic</td>
</tr>
<tr>
<td>18 Month(s)</td>
<td>Mouse</td>
<td>Subcutaneous</td>
<td>0.059 mg/day</td>
<td>LOEL Malignant tumors, Female reproductive system, Mammary Gland</td>
</tr>
<tr>
<td>40 Week(s)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>200 mg/kg/day</td>
<td>LOEL Malignant tumors, Liver</td>
</tr>
<tr>
<td>19 Week(s)</td>
<td>Female</td>
<td>Mouse</td>
<td>Subcutaneous 25 mg/kg (5 days/week)</td>
<td>LOEL Tumors, Mammary gland</td>
</tr>
</tbody>
</table>

Carcinogen Status: See below

Progesterone

- IARC: Group 2B (Possibly Carcinogenic to Humans)
- NTP: Reasonably Anticipated To Be a Human Carcinogen
- OSHA: Listed
Section 12 - Ecological Information

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Progesterone
Predicted 7.4 Log  D 4.04

Mobility in Soil: No data available

Section 13 - Disposal Considerations

Disposal: Dispose of small quantities and empty containers by wrapping with paper and putting in garbage. For larger quantities use a commercial waste disposal service.

Section 14 - Transport Information

The following refers to all modes of transportation unless specified below.

Not regulated for transport under IATA, ADG or IMDG regulations.

Section 15 - Regulatory Information

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Silicone rubber
Australia (AICS): Present

Nylon 66
Australia (AICS): Present

Progesterone
Australia (AICS): Present

Poison Schedule: Schedule 5

Section 16 - Other Information

This SDS contains only safety-related information. For other data see product literature.

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Acronyms:

ADG Code Australian Code for the Transport of Dangerous Goods by Road and Rail (7th edition)
AICS Australian Inventory of Chemical Substances
SWA Safe Work Australia, formerly ASCC and NOHSC
CAS number Chemical Abstracts Service Registry Number
Hazchem Code Emergency action code of numbers and letters that provide information to emergency services especially firefighters
IARC International Agency for Research on Cancer
NOS Not otherwise specified
This version issued: 21 September 2021 and is valid for 5 years from this date

Revision History:

<table>
<thead>
<tr>
<th>Date of Revision</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Apr 2015</td>
<td>Update to GHS</td>
</tr>
<tr>
<td>01 Oct 2016</td>
<td>Corrections to GHS hazard classification, hazard and precautionary statements</td>
</tr>
<tr>
<td>21 Sep 2021</td>
<td>Periodical revision</td>
</tr>
</tbody>
</table>

Contact Points:

<table>
<thead>
<tr>
<th>Zoetis</th>
<th>1800 814 883</th>
</tr>
</thead>
<tbody>
<tr>
<td>Police and Fire Brigade:</td>
<td>Dial 000</td>
</tr>
</tbody>
</table>

If ineffective: Dial Poisons Information Centre (13 11 26 from anywhere in Australia)

THIS SDS SUMMARISES OUR CURRENT AND BEST KNOWLEDGE OF THE HEALTH AND SAFETY HAZARD INFORMATION ABOUT THE PRODUCT DETAILED IN THIS SDS, AND HOW TO SAFELY HANDLE AND USE THE PRODUCT IN THE WORKPLACE FOR THE RECOMMENDED USE. EACH USER OF THE PRODUCT MUST REVIEW THIS SDS IN THE CONTEXT OF HOW THE PRODUCT WILL BE HANDLED AND USED IN THEIR OWN WORKPLACE. IF CLARIFICATION OR FURTHER INFORMATION IS NEEDED TO ENSURE THAT AN APPROPRIATE RISK ASSESSMENT CAN BE MADE, THE USER SHOULD CONTACT ZOETIS.

Please read all labels carefully before using product.

This SDS is prepared in accord with the SWA document “Preparation of Safety Data Sheets for Hazardous Chemicals - Code of Practice” (December 2011) © 2021 Zoetis Inc, All rights reserved.

End of Safety Data Sheet